A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age

Condition:   Avian Influenza Interventions:   Biological: aH5N1c;   Biological: Placebo Sponsors:   Seqirus;   Biomedical Advanced Research and Development Authority Recruiting - verified July 2016

Source: ClinicalTrials.gov - July 18, 2016 Category: Research Source Type: clinical trials